

Special Issue

Cardiology and Cardio-Oncology: Pathogenesis, Diagnosis and Treatment

Message from the Guest Editor


Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology described several shared risk factors that predispose patients to both cardiovascular disease and cancer. Preventive and therapeutic cardiology and cardio-oncology are increasingly evolving, involving multiple metabolic and immunological risk factors. New cardioprotective drugs include SGLT2i, PCSK9i, selective inhibitors of cytokines, chemokines and NLRP-3, improving glucose and lipid homeostasis and chronic low-grade inflammation. This Special Issue welcomes comprehensive reviews, original research articles, communications, systematic reviews and meta-analyses in the field translational and clinical research in diagnostic, preventive and therapeutic cardiology and cardio-oncology, with particular attention on the cardiometabolic risk factors in patients with/without cancer.

Guest Editor

Dr. Vincenzo Quagliariello
Division of Cardiology, IRCCS "G. Pascale", 80131 Naples, Italy

Deadline for manuscript submissions

closed (20 March 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/210554

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).